Get the Stockscreener App
2.83
0.70%
-0.02
After Hours:
2.85
0.02
+0.71%
Sana Biotechnology Inc stock is traded at $2.83, with a volume of 2.01M.
It is down -0.70% in the last 24 hours and down -7.82% over the past month.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
See More
Previous Close:
$2.85
Open:
$2.86
24h Volume:
2.01M
Relative Volume:
0.54
Market Cap:
$787.57M
Revenue:
-
Net Income/Loss:
$-241.99M
P/E Ratio:
-3.0142
EPS:
-0.9389
Net Cash Flow:
$-133.64M
1W Performance:
+0.35%
1M Performance:
-7.82%
6M Performance:
-43.40%
1Y Performance:
+12.30%
1-Day Range:
$2.79
$2.89
1-Week Range:
$2.67
$2.9089
52-Week Range:
$2.53
$6.55
Sana Biotechnology Inc Stock (SANA) Company Profile
Name
Sana Biotechnology Inc
Sector
Industry
Phone
(206) 701-7914
Address
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
2.83 | 793.13M | 0 | -241.99M | -133.64M | -0.9389 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | Wedbush | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Mar-18-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Nov-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-26-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-25-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Aug-14-23 | Initiated | TD Cowen | Market Perform |
| May-02-23 | Initiated | H.C. Wainwright | Neutral |
| Mar-01-21 | Initiated | BofA Securities | Buy |
| Mar-01-21 | Initiated | Goldman | Neutral |
| Mar-01-21 | Initiated | JP Morgan | Neutral |
| Mar-01-21 | Initiated | Morgan Stanley | Overweight |
View All
Sana Biotechnology Inc Stock (SANA) Latest News
Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.14, Implies 230% Upside - TradingView
Sana Biotechnology raises $69M through ATM share sale - MSN
SANA: Gene-modified islet and in vivo CAR T therapies advance toward pivotal trials and key data in 2024 - TradingView
Sana Biotechnology, Inc. - MLQ.ai
SANA SEC FilingsSana Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Bilenker Joshua H. - Moomoo
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director NELSEN ROBERT - Moomoo
Sana Biotechnology Shareholders Reelect Directors and Ratify Auditor - TipRanks
Sana Biotechnology (SANA) director awarded options for 90,000 shares at $2.96 - Stock Titan
Sana Biotechnology (SANA) director granted 90,000 stock options at $2.96 strike - Stock Titan
Director Michelle Seitz gets 90,000 Sana (SANA) stock options - Stock Titan
Sana Biotechnology (SANA) grants director 90,000 stock options at $2.96 - Stock Titan
Sana Biotechnology (SANA) director receives 90,000-share stock option grant - Stock Titan
Sana Biotechnology (SANA) director granted 90,000 stock options at $2.96 - Stock Titan
Sana (SANA) director awarded 90,000 stock options vesting in 2027 - Stock Titan
Sana Biotechnology (SANA) shareholders elect directors, ratify Ernst & Young LLP - Stock Titan
SANA Stock Chart | SANA BIOTECHNOLOGY INC (NASDAQ:SANA) - ChartMill
SANA: Hypoimmune cell therapy and in vivo CAR T trials to start this year, with data expected in 12 months - TradingView
SANA Stock Price, Quote & Chart | SANA BIOTECHNOLOGY INC (NASDAQ:SANA) - ChartMill
Law firm probes Sana Biotech officers for possible shareholder duty breaches - Pluang
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Stream Sana Biotechnology's June investor talks live online - Stock Titan
Seattle InnoSana and Bothell I Following up with ZenLedger - The Business Journals
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - Quantisnow
Sana Biotechnology to Present at June 2026 Investor Conferences - The Manila Times
Sana Biotechnology to present updates at two major healthcare investor conferences in June 2026 - Pluang
RA Capital affiliates report 18.75M Sana Biotechnology shares (NASDAQ: SANA) - Stock Titan
Sana Biotechnology | SCHEDULE 13G: Others - Moomoo
Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Cuts Target Price to $3.07 - Moomoo
InvestingPro Fair Value spotted Sana Biotech overvaluation early By Investing.com - Investing.com Canada
Sana Biotech rises as Mayo Clinic partners for diabetes therapy - MSN
Sana Biotechnology Shares Fall on Sale of $69 Million in Shares Through At-The-Market Facility - Moomoo
Sana Biotechnology Raises $69 Million Through Equity Offering - TipRanks
Sana Biotechnology (SANA) sells 21.6M shares to raise about $69M - Stock Titan
Sana Biotechnology | 8-K: Current report - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Sana Biotechnology Raises $69 Million Through ATM Equity Offering - Moomoo
Sana Biotechnology raises $69 million through stock sale By Investing.com - Investing.com Australia
Sana Biotechnology raises $69 million through stock sale - Investing.com
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through Its At-the-Market (ATM) Facility - 富途牛牛
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs - The Manila Times
Sana presents preclinical data on in vivo CAR T therapy SG293 - Investing.com UK
Sana presents preclinical data on in vivo CAR T therapy SG293 By Investing.com - Investing.com India
BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
SANA: Progress in gene-edited islet and in vivo CAR-T therapies positions the pipeline for major milestones - TradingView
Sana Biotechnology Presents Preclinical Data for In Vivo - GlobeNewswire
A Quick Look at Today's Ratings for Sana Biotechnology(SANA.US), With a Forecast Between $7 to $16 - Moomoo
Sana Biotechnology | 10-Q: Q1 2026 Earnings Report - Moomoo
Sana Biotechnology gains on Mayo Clinic partnership progress despite EPS miss By Investing.com - Investing.com South Africa
Sana Biotechnology | 8-K: Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates - Moomoo
Sana Biotechnology gains on Mayo Clinic partnership progress despite EPS miss - Investing.com India
Sana Biotechnology Inc Stock (SANA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sana Biotechnology Inc Stock (SANA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Harr Steve | President & CEO |
Mar 06 '26 |
Option Exercise |
0.00 |
41,666 |
0 |
7,918,596 |
| Wyrick Susan D. | See Remarks |
Mar 07 '26 |
Option Exercise |
0.00 |
3,250 |
0 |
200,583 |
| Wyrick Susan D. | See Remarks |
Mar 06 '26 |
Option Exercise |
0.00 |
10,416 |
0 |
197,333 |
| Wyrick Susan D. | See Remarks |
Mar 02 '26 |
Option Exercise |
0.00 |
1,525 |
0 |
187,408 |
| Wyrick Susan D. | See Remarks |
Jan 02 '26 |
Option Exercise |
0.00 |
7,500 |
0 |
188,290 |
| Wyrick Susan D. | See Remarks |
Dec 13 '25 |
Option Exercise |
0.00 |
3,400 |
0 |
181,663 |
| Wyrick Susan D. | See Remarks |
Dec 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
180,828 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):